# OnCo record nct04143607 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04143607/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04143607", "NCT04143607" ;
  schema:name "ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC"@en ;
  schema:description "A phase 3 trial of Limertinib run by Jiangsu Aosaikang Pharmaceutical Co., Ltd., active."@en ;
  schema:url <https://onco.cc/trials/nct04143607/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04143607> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2019-07-23" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/limertinib/> ;
  onco:companies <https://onco.cc/companies/aosaikang-pharmaceutical/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct04143607-lancet-respir-med-2025/> .